KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Operating Leases: 2021-2024

Historic Operating Leases for Ionis Pharmaceuticals (IONS) over the last 4 years, with Dec 2024 value amounting to $161.8 million.

  • Ionis Pharmaceuticals' Operating Leases rose 56.01% to $262.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $262.7 million, marking a year-over-year increase of 56.01%. This contributed to the annual value of $161.8 million for FY2024, which is 5.31% down from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Operating Leases of $161.8 million as of FY2024, which was down 5.31% from $170.9 million recorded in FY2023.
  • Ionis Pharmaceuticals' 5-year Operating Leases high stood at $178.9 million for FY2022, and its period low was $19.4 million during FY2021.
  • Its 3-year average for Operating Leases is $170.5 million, with a median of $170.9 million in 2023.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Operating Leases spiked by 820.86% in 2022 and then declined by 5.31% in 2024.
  • Over the past 4 years, Ionis Pharmaceuticals' Operating Leases (Yearly) stood at $19.4 million in 2021, then surged by 820.86% to $178.9 million in 2022, then decreased by 4.51% to $170.9 million in 2023, then decreased by 5.31% to $161.8 million in 2024.